Quest Laboratories Reports Nil Deviation in IPO Fund Utilization for H1 FY27
Quest Laboratories Ltd 路 Others (Uncategorized) 路 12 Nov 2026, 3:25 am
Quest Laboratories Reports Nil Deviation in IPO Fund Utilization for H1 FY27 Quest Laboratories Limited reported zero deviation or variation in the utilization of IPO proceeds for the half-year ended 30th Sep'26. The company raised Rs 43.16 crore by issuing 44,49,600 equity shares at Rs 97 per share. Of the total proceeds, Rs 10.26 crore has been utilized toward manufacturing capex against an allocated Rs 26.00 crore, leaving Rs 15.74 crore unutilized. Full allocations of Rs 10.00 crore for working capital and Rs 3.38 crore for general corporate purposes were completely utilized, alongside Rs 3.59 crore in issue expenses.
Original exchange filing (PDF)
More announcements from Quest Laboratories Ltd
- Quest Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 12 Nov 2026
- Integrated Filing- Financial 路 12 Nov 2026
- Quest Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 11 Nov 2026
- QUEST LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 11-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 11 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 and other business matters 路 11 Nov 2026
- Quest Laboratories Limited has informed the Exchange regarding voting results of Annual General Meeting held on September 29, 2025 路 03 Oct 2026
- Proceedings of the 28th Annual General Meeting 路 30 Sept 2026
- Quest Laboratories Limited has informed the Exchange regarding 'Intimation regarding Strategic Collaboration.'. 路 29 Sept 2026
